100
Participants
Start Date
December 12, 2014
Primary Completion Date
December 12, 2022
Study Completion Date
December 12, 2022
sunitinib
subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
Fifth Medical Center of PLA General Hospital, Beijing
The PLA of 307 Hospital, Beijing
The Affiliated Tumour Hospital of Harbin Medical University, Haerbin
Fudan University Shanghai Cancer Center, Shanghai
Eastern Theater General Hospital,QinHuai District Medical Area, Nanjing
General Hospital of Eastern Theater Command, Nanjing
Nanjing Bayi Hospital, Nanjing
Nanjing General Hospital of Nanjing Military Command/Hepatobiliary Surgery Department, Nanjing
Jiangsu Cancer Hospital, Nanjing
Jiangsu Province Hospital, Nanjing
Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Hefei
Tianjin Medical University General Hospital/General Surgery, Tianjin
Tianjin Medical University General Hospital, Tianjin
Tianjin Cancer Hospital, Tianjin
Zhejiang Cancer Hospital, Oncology department, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
SUN Yat-Sen University Cancer Center, Guangzhou
West China Hospital of Sichuan University/Hepatobiliary Pancreatic Surgery, Chengdu
West China Hospital of Sichuan University, Chengdu
Digestive surgery Department, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an
The First Affiliated Hospital，Air Force Medical University, Xi'an
Air Force Medical University, Xi’an
Lead Sponsor
Pfizer
INDUSTRY